

**Freedom of Information Act 2000****The Royal Cornwall Hospitals NHS Trust Response to Information request****Date Request Received: 15/07/2024****FOI Ref No: 25428****Requested Information:**

Q1. Do you treat patients for Urothelial cancer (Yes or No)?

If No, where do you refer patients for treatment?

Q2. How many patients were treated for Urothelial cancer (any stage) in the past 3 months with the following treatments:

- Atezolizumab (Tecentriq)
- Avelumab (Bavencio)
- Carboplatin single agent or in any other combination
- Carboplatin with Gemcitabine
- Carboplatin with Paclitaxel
- Cisplatin single agent or in any other combination
- Cisplatin with Gemcitabine
- Cisplatin with Gemcitabine + Nivolumab (Opdivo)
- Enfortumab Vedotin + Pembrolizumab (Padcev + Keytruda)
- Nivolumab (Opdivo)
- Pembrolizumab (Keytruda)
- Other active systemic anti-cancer therapy
- Palliative care only

Q3. Does your trust participate in any ongoing clinical trials for the treatment of urothelial cancer?

If so, can you please provide the name of each trial along with the number of patients taking part?

Q4. How many early-stage (non-metastatic or Stages 1-3) non-small cell lung cancer (NSCLC) patients were treated in the past 3 months with:

- Atezolizumab (Tecentriq)
- Durvalumab (Imfinzi)
- Nivolumab (Opdivo)
- Pembrolizumab (Keytruda)
- Chemotherapy
- Radiotherapy
- Chemotherapy AND Radiotherapy

**Response:**

Q1. Do you treat patients for Urothelial cancer (Yes or No)?

**Yes**

Q2. Royal Cornwall Hospitals Trust treated the following numbers of patients for Urothelial cancer (diagnosis codes C65, C66, C67) DURING March to May 2024 with the following treatments:

- Atezolizumab (Tecentriq) **5**
- Avelumab (Bavencio) **6**
- Carboplatin single agent or in any other combination **0**
- Carboplatin with Gemcitabine **4**
- Carboplatin with Paclitaxel **0**
- Cisplatin single agent or in any other combination **1**
- Cisplatin with Gemcitabine **7**
- Cisplatin with Gemcitabine + Nivolumab (Opdivo) **0**
- Enfortumab Vedotin + Pembrolizumab (Padcev + Keytruda) **0**
- Nivolumab (Opdivo) **0**
- Pembrolizumab (Keytruda) **0**
- Other active systemic anti-cancer therapy:
  - Cabozantinib + Nivolumab **1**
  - Denosumab **1**
  - Paclitaxel **1**
- Palliative care only **3**

Q3. Does your trust participate in any ongoing clinical trials for the treatment of urothelial cancer?

If so, can you please provide the name of each trial along with the number of patients taking part?

**Please see below attached file, appendix 1.**

Q4. Royal Cornwall Hospitals Trust treated the following numbers of patients for early-stage (Treatment intent 1-3) non-small cell lung cancer (diagnosis code C34 excluding morphology 80413) during March to June with the following drugs either as a single agent or in combination.:

- Atezolizumab (Tecentriq) **2**
- Durvalumab (Imfinzi) **4**
- Nivolumab (Opdivo) **8**
- Pembrolizumab (Keytruda) **5**
- Other SACT **12**
- Chemotherapy AND Radiotherapy **5**
- Radiotherapy **23**

**Attachment(s):**



FOI 25428  
Urothelial Cancer RL

**Date Response sent: 25/07/2024**